MANKIND - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.8
| Stock Code | MANKIND | Market Cap | 86,849 Cr. | Current Price | 2,103 ₹ | High / Low | 2,727 ₹ |
| Stock P/E | 49.2 | Book Value | 376 ₹ | Dividend Yield | 0.05 % | ROCE | 15.0 % |
| ROE | 13.9 % | Face Value | 1.00 ₹ | DMA 50 | 2,155 ₹ | DMA 200 | 2,285 ₹ |
| Chg in FII Hold | -1.49 % | Chg in DII Hold | 1.35 % | PAT Qtr | 513 Cr. | PAT Prev Qtr | 459 Cr. |
| RSI | 45.4 | MACD | 0.42 | Volume | 3,23,555 | Avg Vol 1Wk | 4,66,297 |
| Low price | 2,012 ₹ | High price | 2,727 ₹ | PEG Ratio | 5.84 | Debt to equity | 0.47 |
| 52w Index | 12.7 % | Qtr Profit Var | 24.5 % | EPS | 41.3 ₹ | Industry PE | 27.6 |
📊 Chart & Trend: Mankind trades at ₹2,103, below both its 50 DMA (₹2,155) and 200 DMA (₹2,285). This indicates short-term and medium-term weakness, with the stock struggling to regain upward momentum.
📉 Momentum Indicators: RSI at 45.4 shows neutral momentum, leaning slightly bearish. MACD at +0.42 is flat, signaling indecision. Bollinger Bands suggest price is mid-range, with support near ₹2,050–₹2,100 and resistance around ₹2,150–₹2,200.
📈 Volume Trends: Current volume (3.23 lakh) is lower than the 1-week average (4.66 lakh), reflecting reduced participation and lack of strong buying interest.
🔑 Entry Zone: ₹2,050–₹2,100 (near support and oversold levels).
🚪 Exit Zone: ₹2,150–₹2,200 (near resistance and 50 DMA).
📌 Trend Status: The stock is in consolidation with neutral bias, awaiting a breakout above ₹2,200 or breakdown below ₹2,050.
Positive
- Quarterly PAT improved (₹459 Cr → ₹513 Cr).
- EPS at ₹41.3 indicates steady earnings power.
- ROCE (15%) and ROE (13.9%) show decent efficiency.
- DII holdings increased (+1.35%), showing strong domestic institutional support.
Limitation
- Stock P/E at 49.2 is much higher than industry PE of 27.6.
- PEG ratio at 5.84 suggests expensive valuation relative to growth.
- Dividend yield at 0.05% is negligible.
- 52-week index at 12.7% shows weak performance compared to peers.
Company Negative News
- FII holdings decreased (-1.49%), showing reduced foreign investor confidence.
- Stock trading below both 50 DMA and 200 DMA, signaling weakness.
Company Positive News
- Sequential PAT growth highlights profitability momentum.
- DII stake increased, supporting long-term confidence.
Industry
- Pharma sector PE at 27.6, much lower than Mankind’s valuation of 49.2.
- Sector rotation favors defensive pharma stocks, but valuations remain stretched for premium players.
Conclusion
⚖️ Mankind is consolidating with neutral momentum, trading below key averages. Entry near ₹2,050–₹2,100 offers margin of safety, while exits around ₹2,150–₹2,200 provide profit-taking opportunities. Despite strong profitability and institutional support, high valuations and weak technicals limit upside, though long-term fundamentals remain resilient.
Would you like me to extend this into a peer benchmarking overlay with Sun Pharma, Cipla, and Dr. Reddy’s to highlight Mankind’s relative valuation and technical strength within the pharma sector?